Is XENE or XFOR more undervalued in 2026?

CirclFi compares Xenon Pharmaceuticals Inc. (XENE) and X4 Pharmaceuticals, Inc. (XFOR) using 13 institutional-grade valuation models. XENE has a Quality of Company score of 5.4/10 while XFOR scores 5.1/10.

Which is a better buy — XENE or XFOR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do XENE and XFOR valuations compare?

XENE at $54.79 and XFOR at $4.14 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

XENE vs XFOR Valuation Comparison 2026 — Intrinsic Value Analysis

XENE

Biotechnology

Xenon Pharmaceuticals Inc.

Quality

5.4

out of 10

Value Trap

LOW

Price

$54.79

Last close

Models

12/13

Active

XFOR

Biotechnology

X4 Pharmaceuticals, Inc.

Quality

5.1

out of 10

Value Trap

WARN

Price

$4.14

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	XENE Fair Value	XENE Upside	XFOR Fair Value	XFOR Upside
Bayesian DCF	Intrinsic	$19.57	-64.3%	$2.03	-51.0%
Earnings Power Value	Intrinsic	$24.80	-55.1%	$3.32	-20.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for XENE vs XFOR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

XENE vs XFOR — Which Stock Is More Undervalued?

XENE scores higher with a 5.4/10 quality rating vs XFOR's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Xenon Pharmaceuticals Inc. (XENE) and X4 Pharmaceuticals, Inc. (XFOR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

XENE currently trades at $54.79 with a QOC of 5.4/10, while XFOR trades at $4.14 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).